1252018-28-2

Basic information

• Product Name: (R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one
• Synonyms: (R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one
• CAS NO: 1252018-28-2
• Molecular Formula: C₁₄H₁₅ClN₂O₄
• Molecular Weight: 310.7329
• EINECS: -0
• Mol File: 1252018-28-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 148-149.7 °C
• Boiling Point: 582.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.388±0.06 g/cm3(Predicted)
• PKA: 0.99±0.20(Predicted)
• CAS DataBase Reference: (R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one(1252018-28-2)
• EPA Substance Registry System: (R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one(1252018-28-2)

Safety Data

• Hazardous Substances Data: 1252018-28-2(Hazardous Substances Data)

Usage

General Description

(R)-4-(4-(5-(chloroMethyl)-2-oxooxazolidin-3-yl)phenyl)Morpholin-3-one, also known as TIC10, is a small molecule compound with potential anti-cancer properties. It has been shown to induce tumor cell death and inhibit tumor growth in various preclinical studies. TIC10 works by activating the tumor suppressor gene called TRAIL, which triggers a cascade of events leading to cancer cell death. Additionally, TIC10 has exhibited low toxicity in normal cells, making it a potentially promising therapeutic agent for cancer treatment. Further research and clinical studies are needed to fully understand its mechanism of action and potential applications in cancer therapy.

Upstream product

• 32315-10-9 bis(trichloromethyl) carbonate 
• 1252018-10-2 4-[4-(N-(3-chloro-(2R)-2-hydroxy-1-propyl)amino)phenyl]morpholin-3-one 
• 530-62-1 1,1'-carbonyldiimidazole 
• 446292-04-2 4-(4-nitrophenyl)-3-morpholinone 
• 438056-69-0 4-(4-aminophenyl)morpholin-3-one 
• 122-98-5 2-Anilinoethanol 
• 29518-11-4 4-phenylmorpholin-3-one 
• 51594-55-9 (R)-(-)-epichlorohydrin 
• 1325210-64-7 4-(4-isocyanatophenyl)morpholin-3-one 

Downstream Products

• 446292-10-0 4-[4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl]morpholine-3-one 
• 366789-02-8 Rivaroxaban 
• 1349248-79-8 4-{4-[(5R)-5-(azidomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}-morpholin-3-one 
• 446292-08-6 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-1H-isoindole-1,3(2H)-dione 
• 1424942-78-8 4-{4-[(5S)-5-(N-benzylaminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morphoIin-3-one 
• 1411775-01-3 4-{4-[(5S)-aminomethyI-2-oxo-1,3-oxazolidine-3-yl]-phenyl}-morphoIine-3-one acetate 
• 1372665-04-7 4-{4-[(5S)-5-((dibenzylamino)methyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one 
• 1252018-26-0 4-[4-((R)-5-(iodomethyl)-2-oxo-oxazolidin-3-yl)phenyl]-morpholin-3-one 
• 898543-06-1 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidine-3-yl]phenyl}morpholin-3-one hydrochloride 

Relevant articles and documents

An approach to the anticoagulant agent rivaroxaban via an isocyanate-oxirane cycloaddition promoted by MgI2.etherate

A convergent and efficient synthesis of anticoagulant rivaroxaban was developed using the cycloaddition of commercially available (R)-epichlorohydrin with 4-(morpholin-3-one)phenyl isocyanate catalysed by MgI2 etherate as the key step, in 22% overall yield.

METHOD FOR THE PREPARATION OF SUBSTITUTED OXAZOLIDINONES

The present invention relates to methods for the preparation of a compound having the formula (X). Individual reaction steps as welt as intermediates are additionally claimed.